18076-Lung Cancer-NSCLC-445

Lung Cancer

Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

  • Details

ClinicalTrials.gov ID: NCT03535740
Diagnosis Type: NSCLC
USOR Number: 18076

  • Address

3550 N E Loop 286
Paris, TX 75460
P: (903) 785-0031

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.